"We're not a one-size-fits-all CDMO," said Min Park, CCO of Matica Bio. "Our team works closely with each partner to deliver ...
Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...
Bayer said it was setting up an organisation within its healthcare division to speed up and support cell and gene therapy development, following recent takeovers.
Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...
Earlier this month, Cryoport’s MVE Biological Solutions unveiled new integrated condition monitoring solutions for its MVE SC 4/2 V and 4/3 V series dewars, leveraging advanced Bluetooth and ...
The rapid advancement of biomedical technologies has opened the door to curing previously untreatable diseases, offering hope for longer, healthier, and more productive lives. Innovations such as ...
First investigational allogeneic pluripotent stem cell derived therapy pivotal Phase III clinical trial exPDite-2 with bemdaneprocel started Phase II gene therapy trial REGENERATE-PD with AB-1005 ...
The 2022 Option Agreement between Astellas and Taysha has expiredRegaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus ...
Cell and gene therapies account for 20% of pipeline Parkinson's therapy bemdaneprocel in Phase 3 trial Pharma success urgently needed, says fund manager FRANKFURT, Sept 25 (Reuters) - Bayer's ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Sana Biotechnology, Inc. is working on a gene therapy to cure Type 1 diabetes. Click here to find out why SANA stock is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback